Publication Details
Abstract
Objective: to evaluate the hemodynamic stability, safety, and efficacy of propofol plus midazolam sedation against propofol alone for patient's undergoing endoscopic procedures. Method: A prospective cross-sectional study was carried out at Imam Zain Al-Abidin Hospital from January 3, 2026, to April 20, 2026. After being enlisted, seventy patients undergoing elective endoscopic operations were split into two equal groups. Propofol (0.25–1 mg/kg) was administered intravenously to Group A together with midazolam (0.01–0.1 mg/kg), whereas Group B got propofol (0.25–1 mg/kg) alone. Vital signs were recorded prior to, during, and following the surgery, including heart rate (HR), mean arterial pressure (MAP), and oxygen saturation (SpO₂). Results: The propofol midazolam group had a much longer recovery time (12.83 ± 1.71 min) than the propofol group (11.54 ± 1.40 min; p = 0.002). There were no discernible variations in SpO₂, HR, or MAP between the two groups. Propofol alone was linked to a higher propensity for hypotension, but the combo regimen produced deeper drowsiness with fewer reported side effects. Novelty: For endoscopic procedures, the combination of propofol and midazolam offers safer, more effective anesthesia with fewer side effects than propofol alone.